VANCOUVER, BC, June 25, 2025 (GLOBE NEWSWIRE) -- Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: EATBF) (FSE: 988) (“Digital Asset Technologies” or the “Company”), a technology focused investment issuer, is pleased to announce that its portfolio company LiquidLink AI Corp. (“LinkLink”), will host a new weekly series of X (formerly Twitter) Spaces dedicated to exploring the future of Real World Assets (RWAs) on the XRP Ledger and the Bitcoin Lightning Network. The series will launch on Monday, July 7 at ...

Core Insights - Biogen Inc. announced topline results from the Phase 1 study of salanersen, an antisense oligonucleotide for spinal muscular atrophy (SMA), showing potential for high efficacy and once yearly dosing [1][5] - The Phase 1 study demonstrated substantial slowing of neurodegeneration and clinically meaningful improvements in motor function in children previously treated with gene therapy [2][5] - Biogen is engaging with global health authorities to advance salanersen into registrational studies based on encouraging Phase 1 data [4][5] Study Details - The Phase 1 study included two parts: a randomized placebo-controlled segment in healthy adults and an open-label segment in pediatric SMA participants who had previously received ZOLGENSMA [2][4] - Interim results from the open-label segment (n=24) indicated that both 40 mg and 80 mg doses of salanersen were well-tolerated, with a mean reduction in neurofilament light chain (NfL) of 70% at 6 months [2][4] - Exploratory data showed that half of the participants (4 out of 8) achieved new WHO motor milestones after receiving salanersen [3][4] Safety Profile - The safety profile of salanersen was generally well-tolerated, with most adverse events being mild to moderate, including pyrexia and upper respiratory tract infections [4][5] - The study's findings suggest that salanersen could address critical unmet needs in SMA treatment, building on Biogen's extensive experience in the field [3][5] Industry Context - SMA is a rare genetic neuromuscular disease affecting approximately 1 in 10,000 live births, characterized by progressive muscle atrophy and weakness [7][8] - SPINRAZA, another treatment for SMA, has been approved in over 71 countries and has treated more than 14,000 individuals worldwide, establishing a foundation of care in SMA [9][10]

ToNasdaq Copenhagen A/S Executive ManagementBernstorffsgade 401577 København Vwww.rd.dkTelephone +45 7012 530025 June 2025 Company announcement number 54/2025 Fixing of coupon rate effective from 1 July 2025 With effect from 1 July 2025, the coupon rate of the following bonds financing RD Euribor3®, RD Stibor3®, RD Stibor3® Green, RD Nibor3®, RD Cibor6®, RD Cibor6® Green and FlexKort® will be adjusted. Please find the data in the attached file. The Executive Management Any additional questions should be ...

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK), (“EnviroGold,” or the “Company”), a clean technology company specialising in the reprocessing mine waste to recover precious, base and strategic metals, is pleased to announce the release of its Q3 Investor Presentation. The presentation reflects the Company’s recent progress in the execution of its commercialisation strategy and planned near term initiatives. The new presentation highlights the Compa ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KY ...

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the "Company" or "Emerita") has appealed the ruling of the Tribunal Superior De Justicia De Andalucia (the "Court") of the Administrative Court with respect to Emerita's complaint filed in 2017 (the "Complaint") against the Junta de Andalucia (the "Junta"), specifically, the Andalucian government panel that awarded the Aznalcóllar public tender (the "Tender"), requesting that the Court rule that (i) t ...

The following resolutions were passed at the Annual General Meeting (the "AGM") of ZetaDisplay AB (publ) ("the Company") on 25 June 2025. Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement and consolidated income statement for the financial year 2024 as well as the balance sheet and consolidated balance sheet as of 31 December 2024. The members of the Board of Directors and the managing director were discharged from liability for the fi ...

DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage im ...

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Reported quarterly adjusted diluted earnings per share of $0.39 Total assets under management and fee-earning assets of $53.5 billion Declared quarterly dividend per share to 12.5 cents AGF Management Limited (AGF or the Company) (TSX: AGF.B) today announced financial results for the second quarter ended May 31, 2025. "Through a challenging environment, we experienced our fourth consecutive quarter of positive retail mutual fund and mutual fund net sales outpacing ...

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Nobel Resources Corp. (TSX – V: NBLC) (the “Company” or “Nobel”) is pleased to provide an update on progress at its Cuprita Project (the “Project” or “Cuprita”) in Atacama Region, Chile. Nobel geologists have identified a leach cap at Cuprita with an associated copper, lead and zinc anomaly in soils. The leach cap and soil anomaly are located adjacent to a ground magnetic low and are situated near the intersection of a major north-northeast striking fault structure ...